Shares in this article
(unusual words added in heading)
THOUSAND OAKS (dpa-AFX) – The US biotech group Amgen was able to more than compensate for declines in sales of older products thanks to strong sales of newer drugs. Overall, revenues in the third quarter rose by 12 percent to 6.4 billion US dollars, the company announced on Wednesday after the market closed in the United States. The bottom line grew by three percent to a good two billion dollars.
For the full year, Amgen now expects sales of $ 25.1 to 25.5 billion. So far the spread had been $ 100 million at both ends. On the other hand, the company has become more optimistic about earnings per share. Here, 15.80 to 16.15 dollars should now be reached (previously: 15.10-15.75). The Covid-19 pandemic continues to have a negative impact on drug sales, the statement said. However, these came back a little as more people went to their doctor again.
Investors took the news calmly. In the aftermarket, Amgen’s share price has recently been almost unmoved./he